quantisnow
FeedTopReportsPricing
⌘K
Live feed
16:15:43·1295d
INSIDERFiling
Global Blood Therapeutics Inc. logo

SEC Form 4: Johnson David Lee gifted 22,000 shares and returned 34,384 shares to the company, closing all direct ownership in the company (withholding obligation)

GBT· Global Blood Therapeutics Inc.
Health Care
Original source

Companies

  • GBT
    Global Blood Therapeutics Inc.
    Health Care

Recent analyst ratings

  • Aug 8UpdateWilliam Blair-
  • Aug 8UpdateCanaccord Genuity$72.00
  • Mar 28UpdateWedbush$71.00
  • Feb 28UpdateMorgan Stanley$31.00
  • Feb 24UpdateOppenheimer$86.00
  • Dec 21UpdateSVB Leerink$53.00

Related

  • PR367d
    Deep Track Capital Files Definitive Proxy Statement and Sends Letter to Fellow Shareholders
  • PR428d
    Deep Track Capital Nominates Four Highly Qualified Candidates for Election to Dynavax Technologies' Board of Directors at 2025 Annual Meeting
  • 13D/G1165d
    SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)
  • 13D/G1169d
    SEC Form SC 13G/A filed by Global Blood Therapeutics Inc. (Amendment)
  • NEWS1260d
    White House Says It Will Continue To Monitor Developments On Cryptocurrencies
  • SEC1285d
    SEC Form 15-12G filed by Global Blood Therapeutics Inc.
  • INSIDER1295d
    SEC Form 4: Patrick Deval L returned 9,037 shares to the company, closing all direct ownership in the company to cover withholding tax
  • INSIDER1295d
    SEC Form 4: Thompson Alexis A. returned 3,308 shares to the company, closing all direct ownership in the company to satisfy tax liability
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022